tirzepatide data GLP-1 trends 2025: real-world data, patient outcomes & future therapies These retrospective tirzepatide data from

In HFpEF female rats aged 18 to 22 months, liraglutide reduced myocardial hypertrophy and the attenuation of atrial weight, as well as improved myocardial fibrosis, which contributed to the reduction of cardiometabolic dysregulation [92]

Through comprehensive research citations, this article will ensure the reader has access to the evidence base underpinning the discussion, facilitating a deeper understanding of the topics covered

Interestingly, about half of users stop taking these medications within a year, a dropout rate similar to lifestyle programs

Tirzepatide has come out on top in multiple literature reviews and trials

Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Walzem RL, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A

Nat Rev Mol Cell Biol 21(7):363383